Nasdaq 100 Stocks SEC Filings — May 13, 2026

13-05-2026

CareView Communications Inc reported Q1 2026 total revenues of $2,191,342, down 2% YoY from $2,239,347, driven by a 17% decline in sales-based software bundle revenue to $935,654 despite growth in subscription-based revenue (+3% to $1,017,483) and equipment packages (+97% to $238,205). Operating income improved to $30,843 from a $134,710 loss YoY due to 9% lower operating expenses, resulting in a smaller net loss of $756,200; however, cash flows from operations turned negative at $126,166 from $267,881 YoY, reducing cash to $1,411,435.

• · Accrued interest payable increased to $23,698,264 as of Mar 31, 2026 from $22,896,139 at Dec 31, 2025.
• · Stock-based compensation expense of $150,302 in Q1 2026.
• · Contract liabilities balance decreased to $2,618,960 end Q1 2026 from $3,158,474 end Q1 2025.

13-05-2026

Cisco reported record Q3 FY2026 revenue of $15.8 billion, up 12% YoY, driven by 17% product revenue growth including 25% in Networking, though services revenue declined 1%, Collaboration fell 1%, and Security was flat. GAAP EPS increased 37% to $0.85 with net income up 35% to $3.4 billion, while non-GAAP EPS rose 10% to $1.06; however, GAAP gross margin contracted to 63.6% from 65.6% and cash flow from operations decreased 7% to $3.8 billion. The company raised FY2026 AI infrastructure revenue guidance to $4 billion and overall revenue to $62.8-63.0 billion.

• · Q4 FY2026 guidance: Revenue $16.7-16.9 billion; GAAP EPS $0.80-0.85; non-GAAP EPS $1.16-1.18
• · FY2026 guidance: Revenue $62.8-63.0 billion; GAAP EPS $3.16-3.21; non-GAAP EPS $4.27-4.29
• · Quarterly dividend declared $0.42 per common share, payable July 22, 2026 to shareholders of record July 6, 2026
• · Total product orders up 35% YoY, up 19% excluding hyperscalers
• · Campus networking orders >25% YoY growth; data center switching orders >40% YoY growth
• · Remaining Performance Obligations (RPO) $43.5 billion, up 4% YoY; product RPO up 6% with long-term $11.7 billion up 6%
• · Cash and cash equivalents and investments $16.6 billion
• · Returned $2.9 billion to stockholders via buybacks and dividends in Q3

13-05-2026

Dyadic International Inc. reported total revenue of $1,110,956 for the three months ended March 31, 2026, a 182% YoY increase from $393,572, driven by higher research and development revenue (+120%), grant revenue (+132%), and new license and milestone revenue of $220,000. Despite revenue growth, the company recorded a net loss of $1,954,683, improved 4% from $2,027,579 YoY, but with total costs and expenses rising 26% to $3,013,649 due to higher general and administrative expenses (+10%), while R&D expenses were flat to slightly down. Net cash used in operating activities was $1,963,334, similar to $1,949,731 prior year, leaving cash, equivalents, and restricted cash at $5,155,728.

• · Accounts receivable decreased to $996,464 at March 31, 2026 from $1,090,297 at December 31, 2025.
• · Stock-based compensation expense declined to $139,299 in Q1 2026 from $225,030 in Q1 2025.

13-05-2026

This 10-K/A amendment filed on May 13, 2026, updates Item 15 with exhibits including governance documents like bylaws amended September 20, 2024, and the 2025 Stock Option and Incentive Plan approved November 7, 2025. It lists material contracts such as development agreements with Norbrook Laboratories (amended through 2024), multiple lease amendments with TVP, LLC, executive compensation and employment agreements for Michael F. Brigham, Bobbi Jo Brockmann, Timothy C. Fiori, and Olivier te Boekhorst, and various debt instruments with Gorham Savings Bank, Maine Technology Institute, and Maine Community Bank. No financial performance data, period comparisons, or operational metrics are provided.

• · Certificate of Amendment to Certificate of Incorporation effective June 11, 2020.
• · Insider Trading Policy adopted December 11, 2024.
• · Employment Agreement with Olivier te Boekhorst dated September 29, 2025.

13-05-2026

Adicet Bio reported Q1 2026 financial results with R&D expenses decreasing 23% YoY to $17.5M and G&A expenses dropping 42% YoY to $4.1M, resulting in a narrower net loss of $20.2M ($1.88 per share) compared to $28.2M ($4.96 per share) in Q1 2025. Cash, cash equivalents, and short-term investments stood at $137.6M as of March 31, 2026, down from $158.5M at year-end 2025, providing runway into 2H 2027. The company anticipates key clinical updates for prula-cel in mid-2026 and plans regulatory submission for ADI-212 in 3Q 2026.

• · Working capital of $121.8M as of March 31, 2026 vs $139.4M as of December 31, 2025.
• · Accumulated deficit of $(634.9M) as of March 31, 2026.
• · Total stockholders’ equity of $140.1M as of March 31, 2026.

13-05-2026

Group One Trading LLC, a Delaware-incorporated entity based in Chicago, IL, filed its 13F-HR on May 13, 2026, disclosing institutional holdings as of March 31, 2026, consisting primarily of sole ownership in equity shares, call options, and put options across biotech, technology, ETFs, and other sectors. Largest positions include call options on AST SpaceMobile Inc Cl A (value $219,986,702,000 underlying 2,654,600 shares), ARK Innovation ETF calls (value $96,356,304,000 underlying 1,425,600 shares), and AXT Inc calls (value $35,555,520,000 underlying 624,000 shares), alongside substantial put options such as on AT&T Inc ($20,214,727,000). The portfolio reflects a trading-oriented strategy with both directional calls and protective/hedging puts, all held solely with no other managers.

• · All positions held solely (SOLE) with zero voting authority shared with other managers
• · Holdings include a mix of common stock shares (SH), call options (Call), and put options (Put)
• · Filer's business address: 425 S Financial Place, Suite 3400, Chicago, IL 60605
• · Conformed period of report: 2026-03-31

13-05-2026

Metals Acquisition Corp. II, a SPAC, reported net income of $177,312 for the three months ended March 31, 2026, driven by $333,883 in interest income from the Trust Account offsetting $156,571 in general and administrative expenses. The company completed its IPO, raising net proceeds of $225,399,999 from Units and $7,600,000 from private placement warrants, depositing $230,000,000 into the Trust Account and growing total assets to $232,670,545 from $132,072 at December 31, 2025. However, shareholders' deficit widened to $(7,034,960) from $3,511 due to accretion of redeemable shares, and net cash used in operating activities was $202,759.

• · Class A ordinary shares subject to redemption valued at $10.01 per share.
• · Net cash used in operating activities: $202,759.
• · Net cash used in investing activities: $230,000,000.
• · Net cash provided by financing activities: $232,364,089.

13-05-2026

Acadia Realty Trust reported strong Q1 2026 NOI growth with total pro-rata NOI up 19% YoY to $55.1M, driven by REIT NOI increasing 14% to $41.8M and Investment Management NOI surging 38% to $13.2M, alongside same-property NOI growth of 5.9%. FFO as Adjusted per diluted share rose 11% YoY to $0.30, supported by Adjusted EBITDA up 3% to $58.6M; however, NAREIT FFO declined 24% to $0.26 per share due to a $31.0M gain on dispositions, and other property income fell 13% YoY.

• · 2026 Guidance: FFO As Adjusted per diluted share $1.22 - $1.26; Annual same-property NOI 5% - 9%.
• · Net Debt to Adjusted EBITDA 5.5x as of Mar 31, 2026 (vs 5.7x Mar 31, 2025).
• · Fixed charge coverage ratio (annualized) 3.5x Q1 2026 (vs 4.0x Q1 2025).
• · Dividends declared per common share/OP unit unchanged at $0.20.
• · FFO As Adjusted payout ratio 68% Q1 2026 (vs 79% Q1 2025).

13-05-2026

Altimmune reported a widened net loss of $22,563 for Q1 2026 compared to $19,575 in Q1 2025, driven by higher R&D expenses ($16,192, up 2%) and significantly increased G&A expenses ($8,052, up 34%), with revenues remaining negligible at $0 versus $5. However, the company bolstered its liquidity through equity financings including a direct offering netting $70M and ATM offerings netting $8.7M, increasing total cash and equivalents to $97,643 from $43,802 at year-end 2025 and total assets to $335,630 from $279,929. EPS improved to $(0.18) from $(0.26) due to increased shares outstanding.

• · Net cash used in operating activities increased to $20,942 in Q1 2026 from $16,840 in Q1 2025.
• · Term loan noncurrent liability: $34,505 as of March 31, 2026.
• · Stock-based compensation expense: $3,378 in Q1 2026.
• · Impairment loss on long-lived asset: $709 in Q1 2026.

13-05-2026

Texas Precious Metals Trust filed an S-1/A registration statement on May 13, 2026, for an IPO of shares (symbol YSAG) backed entirely by physical silver held in U.S. vaults in Shiner, Texas, and Hempstead, New York, aiming to track the LBMA Silver Price minus a 0.39% annualized Sponsor’s Fee. Baskets consist of 10,000 shares created or redeemed with 10,000 Troy Ounces of physical silver by Authorized Participants only. The filing highlights operational details including roles of the Trustee, Administrator, Transfer Agent (USBGFS), Marketing Agent (PINE Distributors LLC), and Custodian, while noting risks such as silver price volatility, lack of active management, and potential central bank sales impacting value.

• · Custodian vaults: TPMD Shiner (primary, Texas) and TPMD Hempstead (satellite, New York); silver segregated and not co-mingled.
• · Fund is an emerging growth company under JOBS Act, opting out of extended accounting transition period.
• · Net asset value calculated daily using LBMA Silver Price as of 4:00 PM EST.
• · Minimum creation/redemption order: one Basket (10,000 Shares), subject to Sponsor discretion up to four Baskets.

13-05-2026

At the Annual Meeting on May 12, 2026, Community Health Systems, Inc. shareholders elected all 14 director nominees with overwhelming majorities, receiving 81,095,873 to 83,653,444 For votes each against minimal opposition. The non-binding advisory resolution on named executive officer compensation was approved with 81,701,049 For votes versus 1,814,301 Against. Shareholders ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026, with 110,561,632 For votes.

• · Proxy Statement filed with SEC on April 2, 2026
• · Broker non-votes: 27,004,521 for all director and compensation votes; n/a for auditor ratification

13-05-2026

Sun Communities, Inc. formally engaged Deloitte & Touche LLP as its new independent registered public accounting firm effective May 12, 2026, succeeding Grant Thornton LLP, which was dismissed after completing its review of the consolidated financial statements for the period ended March 31, 2026. There were no disagreements or reportable events with Grant Thornton except for a material weakness in internal controls over financial reporting as of December 31, 2024, which was remediated during 2025. Grant Thornton issued a concurring letter dated May 13, 2026, filed as Exhibit 16.1.

• · Original 8-K filed March 27, 2026, disclosing initial appointment of Deloitte.
• · Grant Thornton audit reports for fiscal years ended December 31, 2025 and 2024 were unqualified.
• · No consultations with Deloitte prior to engagement regarding accounting principles, audit opinions, disagreements, or reportable events.

13-05-2026

MultiSensor AI reported first quarter 2026 revenue of $1.6 million, up 38% YoY from $1.2 million, driven by software revenue growth of 169% to $0.7 million. Net loss narrowed 44% YoY to $2.5 million amid disciplined expense management, with strategic deployments at Manchester Airport, a global food provider, and data center pilots. However, gross margin declined 2% to 57%, operating cash flow was negative $1.7 million, and cash equivalents fell to $22.6 million from $24.4 million at year-end.

• · Operating expenses totaled $3,508 thousand in Q1 2026, down from $5,311 thousand in Q1 2025.
• · Net cash used in operating activities was $1,688 thousand in Q1 2026, improved from $3,176 thousand in Q1 2025.
• · Capital expenditures were $121 thousand in Q1 2026.
• · All share amounts adjusted retroactively for 1-for-40 reverse stock split on April 13, 2026.

13-05-2026

Immunic, Inc. reported a Q1 2026 net loss of $32,588 thousand, widening 28% YoY from $25,473 thousand amid higher R&D expenses (up 19% to $25,626 thousand) and G&A expenses (up 44% to $7,609 thousand), while operating cash burn improved to $17,301 thousand from $21,776 thousand. Cash and cash equivalents surged to $186,629 thousand as of March 31, 2026 from $15,483 thousand at year-end 2025, driven by $187,263 thousand net proceeds from a February 2026 private placement and warrant exercises, flipping stockholders' equity to a positive $151,233 thousand from a $6,673 thousand deficit. Total assets reached $189,742 thousand, up significantly QoQ.

• · Weighted-average shares outstanding increased 197% YoY to 30.1 million, improving EPS to $(1.08) from $(2.51).
• · February 2026 Private Placement and exercises of May 2025 warrants contributed $188,642 thousand in financing cash flows.
• · No revenue reported, consistent with clinical-stage biotech operations.

13-05-2026

Atmus Filtration Technologies Inc. issued a press release announcing that its Board of Directors declared a quarterly cash dividend of $0.055 per common share. The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 26, 2026. No other financial metrics or performance comparisons were disclosed.

• · Filing date: May 13, 2026
• · Record date: May 26, 2026
• · Payment date: June 10, 2026

13-05-2026

State Farm Mutual Automobile Insurance Co filed its 13F-HR on May 13, 2026, reporting total portfolio holdings value of $126,857,699,157 as of March 31, 2026, with no changes in shares or values across all positions from the prior quarter, indicating flat performance. Top holdings include Apple Inc (combined value $5,963,260,993), Exxon Mobil Corp ($5,180,740,098), and Walmart Inc ($4,851,286,013), spanning sectors like technology, energy, and consumer staples. The portfolio consists of both sole discretionary and defined (DFND) shares managed through affiliates like Northern Trust Investments, Inc.

• · All reported positions show 0 change in shares (ΔSH) and 0 change in value (ΔVAL) from prior quarter.
• · Portfolio includes 197 holdings (as indicated in filing).
• · Filed under SEC file number 028-00534.

13-05-2026

NexMetals Mining Corp. reported total assets of $98,518,580 as of December 31, 2025, up from $24,953,469 in 2024, bolstered by $126,000,070 in financing proceeds, cash rising to $39,780,384 from $6,105,933, and exploration assets increasing to $42,730,629. However, the net loss widened to $59,086,325 from $42,420,283, driven by higher general exploration expenses ($36,113,842 vs. $29,651,360), investor relations costs surging to $4,981,937 from $362,933, and cash used in operations growing to $47,580,572 from $37,599,434. Shareholders' equity flipped to a positive $82,949,790 from a $3,447,060 deficiency amid share issuances totaling over 26 million new common shares.

• · Term loan of $18,983,212 extinguished via share issuance valued at $17,727,018 plus warrants $7,398,104.
• · Impairment loss of $501,497 recorded in 2025.
• · Loss on term loan extinguishment $5,982,434 in 2025.
• · Going concern evaluation by auditors, with cash flow forecasts assessed for 12 months.
• · Common shares issued: 14,035,100 public offering, 8,394,953 private placement, 3,768,941 debt conversion.

13-05-2026

Jaws Mustang Acquisition Corp reported net income of $269,426 for Q1 2026, swinging from a $507,977 net loss in Q1 2025, primarily due to a $372,250 positive change in fair value of warrant liabilities versus a $372,250 negative change YoY; G&A expenses declined 24% YoY to $108,814. However, the company recorded an operating loss of $108,814 and total liabilities rose 2% QoQ to $7,333,832 amid increasing promissory notes from related parties; shareholders' deficit improved slightly to $(6,870,727) from $(7,134,163) QoQ but remains deeply negative.

• · Cash held in Trust Account increased slightly QoQ to $1,067,566 from $1,061,576.
• · Accrued expenses rose QoQ to $1,229,811 from $1,169,888.
• · Net cash used in operating activities improved to $68,076 from $165,902 YoY.
• · Proceeds from promissory notes - related party: $435,771 in Q1 2026.

13-05-2026

For the three months ended March 31, 2026, Muzinich Corporate Lending Income Fund reported total investment income of $1,888,885, up 3.1% YoY from $1,833,704, driven by higher interest income, while net investment income increased 18.0% to $1,435,377 due to reduced expenses and a management fee waiver. However, a net unrealized depreciation of $1,024,954 (vs. $285,101 appreciation YoY) resulted in a net increase in net assets from operations of only $435,844, down 71.7% YoY from $1,537,313, and per share $4.60 vs. $16.30. Net assets rose slightly QoQ to $96,874,819 with NAV per share at $1,021.76 (up 0.5% from $1,017.15), though cash equivalents dropped sharply to $854,731 from $7,136,024.

• · Amortized cost of non-controlled/non-affiliated investments: $97,060,981 as of Mar 31, 2026 (vs. $86,632,872 as of Dec 31, 2025).
• · No stockholder distributions in Q1 2026 (vs. $331,664 in Q1 2025).
• · Net cash used in operating activities: $5,337,975 in Q1 2026 (vs. provided $4,336,614 in Q1 2025).

13-05-2026

Formula Systems (1985) Ltd reported annual revenues of $2,627,124 thousand in 2025, up 18% YoY from $2,218,434 thousand in 2024, with both years' figures adjusted to exclude Sapiens following its acquisition by Advent in November 2025. Growth was driven by strong performance in Israel (+21% to $2,092,849 thousand) and the United States (+12% to $435,800 thousand); however, Europe declined 5% to $83,866 thousand, Japan fell 6% to $11,920 thousand, and Other regions dropped 35% to $2,689 thousand. The filing highlights macroeconomic risks including inflation, high interest rates, and tariffs potentially pressuring future revenues and cash flows.

• · Sapiens results deconsolidated from 2025 income statements and excluded from 2024 comparative revenues per IFRS 5.
• · Risks include global macroeconomic headwinds from inflation, high interest rates, geopolitical developments, tariffs, regulatory changes, and currency fluctuations.
• · Hermes Cargo is a cloud-first SaaS solution for air cargo management, covering handling, documentation, customs, tracking, security, and billing.

13-05-2026

Barrow Hanley Mewhinney & Strauss LLC filed a Schedule 13G on May 13, 2026, disclosing beneficial ownership of 9,261,674 shares of Warner Music Group Corp. common stock, representing 6.30% of the outstanding shares as of March 31, 2026. The shares consist of 6,782,967 and 2,478,707 held with shared voting and dispositive power. The filing certifies passive investment under Rule 13d-1(b), held in the ordinary course of business without intent to influence control.

• · Filed under Rule 13d-1(b) as an Investment Adviser (IA)
• · Date as of change: 03/31/2026
• · Filing confirms no purpose of changing or influencing control of the issuer

13-05-2026

Intelligent Bio Solutions Inc. reported revenue of $1,060,802 for the three months ended March 31, 2026, up 45.5% YoY from $728,867, with gross profit rising 56.8% to $535,381; over nine months, revenue increased 39.0% to $3,069,373. However, net loss widened to $2,869,640 in Q3 (from $2,550,674) and $8,551,245 over nine months (from $7,502,270), amid higher operating expenses and increased cash burn from operations to $8,744,914. Cash rose to $6,862,204 from $1,019,909, supported by $14,671,717 in financing from stock issuances, while total assets grew to $14,862,792.

• · UK revenue $1,041,152 (98% of Q3 total) up from $707,777 YoY, while APAC, Americas, and Rest of World remained minimal.
• · Operating expenses rose to $3,648,177 in Q3 from $3,074,968, driven by higher development expenses.
• · Shares outstanding increased from 732,338 at June 30, 2025 to 2,001,185 at March 31, 2026 via ATM offerings and warrant exercises.
• · Government support income slightly down to $165,695 in Q3 from $173,271.

13-05-2026

Tharimmune, Inc. reported a sharply widened net loss of $47,343,197 for the three months ended March 31, 2026, compared to $2,541,704 in the prior year period, driven by general and administrative expenses surging to $36,600,488 from $1,952,599 and a $15,013,304 unrealized loss on digital assets. However, the company significantly strengthened its balance sheet with cash increasing 144% QoQ to $41,532,140, digital assets rising 7.9% to $541,569,363, and total assets growing to $584,654,613, fueled by $86,956,878 in net financing proceeds from stock offerings. Stockholders' equity expanded to $469,799,318 amid heavy share dilution, while the clinical-stage biotech segment assets declined to $1,655,101 from $5,181,535.

• · Weighted average common shares outstanding basic and diluted: 207,705,905 for Q1 2026 vs 2,572,715 for Q1 2025.
• · Net cash used in investing activities: $54,822,298 for digital asset purchases in Q1 2026 (none in Q1 2025).
• · Deferred tax benefit: $4,220,240 in Q1 2026.
• · Stock-based compensation: $32,259,757 in Q1 2026 vs $219,179 in Q1 2025.

13-05-2026

Community Financial System, Inc. (NYSE: CBU) filed an 8-K on May 13, 2026, under Item 7.01 Regulation FD Disclosure, announcing that it posted an investor presentation to its website for use in upcoming meetings with investors and analysts. The presentation is accessible on the Events & Presentations page of the Company’s investor relations website at www.communityfinancialsystem.com.

13-05-2026

Acadian Asset Management LLC filed its 13F-HR report on May 13, 2026, disclosing equity holdings as of March 31, 2026, across a diverse portfolio heavily weighted toward technology, biotech, and healthcare sectors. Top positions include Apple Inc. ($3.89B, 15.34M shares), Alphabet Inc. Class A ($2.35B, 8.18M shares), and Amazon.com Inc. ($1.28B, 6.14M shares), with no reported changes, additions, or reductions indicated in the filing. The portfolio features over 1,900 securities with a focus on large-cap U.S. names and no derivatives or short positions noted.

• · All positions reported as defined shares (SH DFND) with full investment discretion and no put/call activity.
• · Portfolio includes significant biotech exposure (e.g., Alector Inc. 4.04M shares, Atea Pharmaceuticals Inc. 1.58M shares).
• · No voting authority details beyond standard sole/shared/none columns all at 0.